首页> 外文会议>AIChE Annual Meeting >A Drug Quality System for the 21 st Century:Process Analytical Technology (PAT) a Framework for Scientific Risk-Based Regulation of Pharmaceutical Quality
【24h】

A Drug Quality System for the 21 st Century:Process Analytical Technology (PAT) a Framework for Scientific Risk-Based Regulation of Pharmaceutical Quality

机译:21世纪的药物质量体系:工艺分析技术(PAT)基于科学风险的药物质量调节框架

获取原文

摘要

FDA oversees the quality of drug products using a two- pronged approach involving review of information submitted in applications as well as inspection of manufacturing facilities for conformance to requirements for current Good Manufacturing Practice (Cgmp). These two programs have served the country well by helping to ensure the quality of drug products available in the US. Now, as we approach the 25 th anniversary of the last major revision to the drug CGMP regulations, it is time to step back and evaluate the currency of these programs so that: (1) the most up-to-date concepts of risk management and quality systems approaches are incorporated while continuing to ensure product quality; (2) the latest scientific advances in pharmaceutical manufacturing and technology are encouraged; (3)the submission review program and the inspection program operate in a coordinated and synergistic manner; (4) regulation and manufacturing standards are applied consistently; (5) management of the program encourages innovation in the pharmaceutical manufacturing sector; and (6) FDA resources are used most effectively and efficiently to address the most significant health risks. This presentation will discuss various elements of a new FDA draft guidance entitled "PAT-^sA Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance. The draft guidance is part of the Agency's August 2002 initiative, and is intended to facilitate progress to the desired state of pharmaceutical manufacturing described in this presentation.
机译:FDA使用双管齐下的方法监督药品的质量,涉及审查申请中提交的信息以及对当前良好制造实践的要求(CGMP)的符合要求的制造设施的检查。这两个方案通过帮助确保美国药品的质量提供服务。现在,正如我们对毒品委员会规定的最后一次重大修订的第25周年,现在就是返回并评估这些方案的货币的时间,以至于:(1)风险管理最新概念并在继续确保产品质量的同时纳入了质量系统的方法; (2)鼓励制药制造和技术的最新科学进展; (3)提交审查计划和检查计划以协调和协同的方式运作; (4)规定和制造标准始终应用; (5)该计划的管理鼓励制药制造业的创新; (6)FDA资源最有效地使用,以解决最重要的健康风险。本演示文稿将讨论新的FDA草案指南的各种要素,题为“专利制药制造和质量保证的框架。指导草案是该机构2002年8月的一部分倡议,旨在促进进入所需的国家本介绍中描述的药物制造。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号